ZIOPHARM Commences Treatment Of First Patients In Two Separate Phase I/II Combination Studies Of Both Indibulin And Palifosfamide

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced that dosing of the first patient took place in two separate new studies, including: - A Phase I/II combination study evaluating oral indibulin (ZIO-301) combined with oral Tarceva® (erlotinib) in the treatment of patients with solid tumors, and - A Phase I/II study of palifosfamide (ZIO-201) used in combination with Adriamycin® (doxorubicin) in the treatment of patients with sarcoma.

More: continued here

Filed under: Cancer on February 7th, 2008